It’s been a mixed two weeks for small-cap health companies, with 64 companies gaining ground, 47 losing it and 25 flatlining.

Actinogen Medical (ASX:ACW) was the biggest gainer, up 31% on no news.

Followed by Paradigm Biopharmaceutical (ASX:PAR) which jumped 27% off the back of written feedback from the US FDA in relation to its Investigation New Drug (IND) submission for pentosan polysulfate sodium (PPS) to treat pain related to knee osteoarthritis.

The FDA has one outstanding question regarding adrenal gland function related to a preclinical finding in the adrenal gland of rats, which is the focus of the ongoing US FDA review.

“I am confident that the FDA and Paradigm have now attained a pathway to commence our Phase 3 clinical trial in the US,” says Paradigm CEO, Paul Rennie.

The company also recently received Australian ethics approval for its pivotal Phase 3 clinical trial, PARA_OA_002, to evaluate the treatment effects of PPS against placebo on participants with knee osteoarthritis pain.

Next up was Oventus Medical (ASX:OVN) up 23%, followed by Hexima (ASX:HXL) up 22% – both on no news.

Medical Developments (ASX:MVP) was up 21% after releasing its FY21 annual report which detailed a strong rebound of Penthrox sales in the first half.

Gross Revenue in FY21 was $25.7m, growing 9% from the $23.6m achieved in the comparable period.

Respiratory product sales, whilst slightly improved in the second half, were depressed in FY21 as a result of the milder cold and flu season as well as reduced community movement and ongoing improved community hygiene practices.

 

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Code Company Price %Mth %Wk MktCap
ACW Actinogen Medical 0.13 41 31 $ 217,419,611.11
PAR Paradigm Bio. 2.26 18 27 $ 459,002,840.58
OVN Oventus Medical Ltd 0.135 48 23 $ 33,841,714.90
HXL Hexima 0.45 64 22 $ 53,290,693.78
MVP Medical Developments 5.13 31 21 $ 365,587,767.36
OSP Osprey Med Inc 0.84 -24 20 $ 20,911,711.73
NTI Neurotech Intl 0.05 0 19 $ 34,144,137.17
IBX Imagion Biosys Ltd 0.076 6 19 $ 86,749,274.42
DXB Dimerix Ltd 0.32 0 16 $ 82,004,710.26
PAB Patrys Limited 0.044 10 16 $ 80,459,073.20
IDT IDT Australia Ltd 0.65 -13 14 $ 152,311,207.95
MEB Medibio Limited 0.009 20 13 $ 14,360,491.98
RHY Rhythm Biosciences 1.3 44 12 $ 277,704,107.73
NOX Noxopharm Limited 0.57 -1 12 $ 171,524,514.53
VLS Vita Life Sciences.. 1.35 9 11 $ 66,079,028.06
SOM SomnoMed Limited 2.4 4 9 $ 198,622,356.00
KZA Kazia Therapeutics 1.58 14 8 $ 205,455,923.95
PXS Pharmaxis Ltd 0.135 23 8 $ 56,800,076.75
AMT Allegra Orthopaedics 0.27 8 8 $ 28,203,984.81
RGS Regeneus Ltd 0.078 0 7 $ 23,675,992.31
TD1 Tali Digital Limited 0.033 -8 6 $ 29,820,985.25
CGS Cogstate Ltd 2.31 38 6 $ 413,660,793.60
VTI Vision Tech Inc 1.025 0 6 $ 24,817,275.00
BIT Biotron Limited 0.053 0 6 $ 38,606,299.22
LSH Lifespot Health Ltd 0.09 -1 6 $ 13,814,290.47
AVE Avecho Biotech Ltd 0.02 18 5 $ 36,722,330.52
ANP Antisense Therapeut. 0.205 11 5 $ 117,767,650.32
OPT Opthea Limited 1.34 -6 5 $ 465,079,691.83
EYE Nova EYE Medical Ltd 0.42 0 5 $ 61,132,592.22
CMP Compumedics Limited 0.42 5 5 $ 74,408,438.16
APH AP Hemp Ltd 0.325 3 5 $ 24,147,942.53
EXL Elixinol Wellness 0.11 0 5 $ 34,698,666.86
IPD Impedimed Limited 0.115 -12 5 $ 179,442,289.68
NC6 Nanollose Limited 0.094 -3 4 $ 13,976,518.59
M7T Mach7 Tech Limited 1.04 8 4 $ 235,613,728.42
PTX Prescient Ltd 0.27 38 4 $ 174,033,486.36
PAL Palla Pharma Ltd 0.275 -26 4 $ 46,145,251.46
CDY Cellmid Limited 0.057 10 4 $ 11,245,833.60
CAN Cann Group Ltd 0.285 -2 4 $ 90,411,255.38
MDR Medadvisor Limited 0.3 -17 3 $ 117,017,371.52
MX1 Micro-X Limited 0.31 15 3 $ 142,507,539.40
RCE Recce Pharmaceutical 0.95 23 3 $ 168,564,511.59
CHM Chimeric Therapeutic 0.325 2 3 $ 73,102,745.92
OCC Orthocell Limited 0.49 1 3 $ 96,719,768.98
ICR Intelicare Holdings 0.098 -18 3 $ 4,569,559.95
CBL Control Bionics 0.68 1 3 $ 33,973,361.55
BNO Bionomics Limited 0.17 -11 3 $ 166,583,462.76
ONE Oneview Healthcare 0.42 15 2 $ 184,222,732.53
PSQ Pacific Smiles Grp 2.6 6 2 $ 426,083,774.46
OSL Oncosil Medical 0.045 -8 2 $ 35,655,448.23
AC8 Auscann Grp Hlgs Ltd 0.091 -5 2 $ 40,530,334.12
SUD Suda Pharmaceuticals 0.05 0 2 $ 23,560,179.31
CYP Cynata Therapeutics 0.53 0 2 $ 75,220,211.85
PBP Probiotec Limited 2.2 -3 2 $ 167,127,054.78
IMM Immutep Ltd 0.55 6 2 $ 455,243,698.54
TRU Truscreen 0.057 -3 2 $ 20,683,376.42
BWX BWX Limited 5.01 -6 2 $ 789,399,995.09
PGC Paragon Care Limited 0.315 7 2 $ 109,812,719.90
BOT Botanix Pharma Ltd 0.069 -7 1 $ 66,173,661.03
ALC Alcidion Group Ltd 0.375 4 1 $ 393,025,894.50
VHT Volpara Health Tech 1.195 3 1 $ 306,650,758.82
IMU Imugene Limited 0.47 36 1 $ 2,676,896,304.18
NEU Neuren Pharmaceut. 2.07 -5 1 $ 258,677,548.48
ONT 1300 Smiles Limited 8.05 1 1 $ 190,610,991.20
PEB Pacific Edge 1.475 $ 1,122,983,376.90
BDX Bcaldiagnostics 0.185 16 0 $ 23,017,148.35
SCU Stemcell United Ltd 0.014 0 0 $ 14,606,489.21
RSH Respiri Limited 0.068 -30 0 $ 50,598,855.30
RHT Resonance Health 0.1 -17 0 $ 46,085,198.10
PYC PYC Therapeutics 0.14 -3 0 $ 429,425,023.91
OSX Osteopore Limited 0.305 -10 0 $ 35,766,812.59
OIL Optiscan Imaging 0.23 10 0 $ 148,364,544.48
NSB Neuroscientific 0.455 38 0 $ 73,887,896.15
MMJ MMJ Group Hlds Ltd 0.08 -4 0 $ 18,396,318.80
MEM Memphasys Ltd 0.066 8 0 $ 48,689,528.32
MDC Medlab Clinical Ltd 0.16 -14 0 $ 54,748,107.36
JTL Jayex Technology Ltd 0.024 0 0 $ 6,479,942.01
ICS ICSGlobal Limited 0.575313 0 0 $ 6,054,604.94
GTG Genetic Technologies 0.007 -7 0 $ 64,582,631.00
FFC Farmaforce Ltd 0.051 -23 0 $ 6,664,729.98
CPH Creso Pharma Ltd 0.115 -4 0 $ 132,172,038.02
ATX Amplia Therapeutics 0.21 2 0 $ 24,964,268.00
ATH Alterity Therap Ltd 0.03 -6 0 $ 72,206,237.34
ALT Analytica Limited 0.002 0 0 $ 9,227,602.26
AHK Ark Mines Limited 0.034 0 0 $ 1,778,919.95
ADR Adherium Ltd 0.016 7 0 $ 31,991,606.03
ACR Acrux Limited 0.125 0 0 $ 36,842,043.94
1ST 1St Group Ltd 0.016 -16 0 $ 6,793,870.45
JHC Japara Healthcare Lt 1.385 1 0 $ 368,801,312.64
ARX Aroa Biosurgery 1.06 -1 0 $ 350,409,386.40
IHL Incannex Healthcare 0.3525 -8 -1 $ 415,083,240.58
SDI SDI Limited 1 -5 -1 $ 124,808,806.50
PNV Polynovo Limited 1.89 -6 -1 $ 1,299,627,506.46
PAA Pharmaust Limited 0.085 -2 -1 $ 26,937,552.56
RAC Race Oncology Ltd 3.36 10 -1 $ 504,114,050.08
DOC Doctor Care Anywhere 0.75 3 -1 $ 140,752,763.38
CAJ Capitol Health 0.375 -1 -1 $ 383,115,579.44
AT1 Atomo Diagnostics 0.345 44 -1 $ 124,650,552.79
MVF Monash IVF Group Ltd 0.955 -6 -2 $ 374,049,446.40
MXC Mgc Pharmaceuticals 0.059 5 -2 $ 140,604,507.52
BPH BPH Energy Ltd 0.0605 -4 -2 $ 39,895,163.34
ZLD Zelira Therapeutics 0.039 3 -3 $ 47,612,918.64
ILA Island Pharma 0.33 -10 -3 $ 13,741,813.12
IMC Immuron Limited 0.155 -3 -3 $ 37,495,688.34
CDX Cardiex Limited 0.06 -2 -3 $ 55,655,638.32
AHC Austco Healthcare 0.14 0 -3 $ 41,207,397.90
UBI Universal Biosensors 0.795 -4 -4 $ 144,844,665.54
NYR Nyrada Inc. 0.26 -9 -4 $ 31,340,225.99
SHG Singular Health 0.245 11 -4 $ 16,173,370.50
PCK Painchek Ltd 0.047 -8 -4 $ 54,326,630.35
DVL Dorsavi Ltd 0.021 -5 -5 $ 7,380,084.01
NXS Next Science Limited 1.335 -7 -5 $ 265,285,038.06
HCT Holista CollTech Ltd 0.058 -6 -5 $ 16,245,596.13
4DX 4Dmedical Limited 1.42 -8 -5 $ 307,164,971.61
GSS Genetic Signatures 1.46 -1 -5 $ 212,408,825.31
S66 Star Combo 0.32 -6 -6 $ 43,107,990.08
AGH Althea Group 0.24 -4 -6 $ 73,614,102.00
PIQ Proteomics Int Lab 0.95 -10 -6 $ 99,993,081.25
CYC Cyclopharm Limited 1.645 0 -6 $ 151,734,087.38
EZZ EZZ Life Science 0.515 16 -6 $ 6,180,000.00
BD1 Bard1 Life Sciences 1.13 -22 -7 $ 103,886,459.60
IVX Invion Ltd 0.014 8 -7 $ 72,014,049.84
ADO Anteotech Ltd 0.27 54 -7 $ 541,857,721.90
1AD Adalta Limited 0.093 -1 -7 $ 22,801,700.75
CTE Cryosite Limited 0.37 -17 -8 $ 18,059,538.31
BXN Bioxyne Ltd 0.024 -27 -8 $ 14,723,344.15
ZNO Zoono Group Ltd 0.405 -30 -8 $ 66,951,646.34
VBS Vectus Biosystems 1.47 13 -8 $ 46,216,875.24
LCT Living Cell Tech. 0.01 -9 -9 $ 5,714,409.81
CU6 Clarity Pharma 1.21 -18 -10 $ 201,850,928.82
LDX Lumos Diagnostics 0.975 -19 -10 $ 145,647,840.61
EPN Epsilon Healthcare 0.125 -14 -11 $ 25,051,903.37
RNO Rhinomed Ltd 0.345 -9 -12 $ 91,371,287.52
GLH Global Health Ltd 0.37 -22 -12 $ 21,511,568.96
RAP Resapp Health Ltd 0.072 50 -12 $ 64,439,780.78
LBT LBT Innovations 0.12 -4 -17 $ 40,476,122.96
TLX Telix Pharmaceutical 5.83 -15 -19 $ 1,661,578,107.20

 

Flat this fortnight was MMJ Group (ASX:MMJ), despite having received an offer from BevCanna Enterprises (CSE:BEV) to acquire 100% of Embark Health Inc for a purchase price of 46.7 million Bevcanna shares – plus potential future earn-outs.

MMJ chairman Peter Wall said the proposed acquisition of Embark Health “would allow MMJ to exit its investment at its book value and retain a share in the potential upside of the larger merged Bevcanna business.”

Creso Pharma (ASX:CPH) was also flat even though wholly-owned psychedelics subsidiary Halucenex Life Sciences secured a research agreement with Acadia University to develop a soft gel capsule drug delivery format containing CBD and psilocybin respectively.

The aim is for the formulation to have a quick release effect, good bioavailability of the active ingredients and rapid action.

“We look forward to receiving the initial results, as they will provide us with valuable insight into the potential steps towards licensing and manufacturing agreements with industry participants,” Creso non-executive chairman Adam Blumenthal.

And despite being awarded the contract for its Hailie sensor and software solution for an upcoming US-based clinical study by AstraZeneca, Adherium (ASX:ADR) also remained flat.

Who’s the biggest loser?

Telix Pharmaceutical (ASX:TLX) was the biggest loser, down 19% after the US FDA has extended the review period for the New Drug Application (NDA) of its prostate cancer imaging investigational product, Illuccix, by three months to 23 December.

And yesterday the company also received a $12.1 million R&D tax refund from the ATO in relation to its activities during the financial year ended 31 December 2020.

Telix also said that its application for an expanded overseas finding to enable partial recovery of essential overseas R&D expenditure, has been accepted by the Department of Industry, Science, Energy and Resources.

And LBT Innovations (ASX:LBT) dropped 17% after its 50% owned joint-venture company signed a five-year agreement for Thermo Fisher to become the exclusive distributor for the APAS Independence in the United States.

The APAS Independence is the first and only FDA-cleared automated culture plate reader available in the US and uses advanced imaging and artificial intelligence to interpret bacterial growth on culture plates.